Scarica l'app Stockscreener
73.96
16.30%
-14.40
Dopo l'orario di chiusura:
76.64
2.68
+3.62%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Precedente Chiudi:
$88.36
Aprire:
$87.54
Volume 24 ore:
2.28M
Relative Volume:
2.78
Capitalizzazione di mercato:
$7.79B
Reddito:
$628.56M
Utile/perdita netta:
$141.82M
Rapporto P/E:
58.70
EPS:
1.26
Flusso di cassa netto:
$142.60M
1 W Prestazione:
-16.10%
1M Prestazione:
+3.27%
6M Prestazione:
+9.20%
1 anno Prestazione:
+63.45%
Intervallo 1D:
$73.12
$87.54
Intervallo di 1 settimana:
$73.12
$91.00
Portata 52W:
$42.01
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Nome
Corcept Therapeutics Inc
Settore
Industria
Telefono
650.688.8803
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Confronta CORT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
73.96 | 9.31B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-06 | Aggiornamento | Truist | Hold → Buy |
| 2023-04-11 | Iniziato | SVB Securities | Market Perform |
| 2023-04-04 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-01 | Downgrade | Truist | Buy → Hold |
| 2022-07-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-06-27 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-02 | Iniziato | Canaccord Genuity | Buy |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2020-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-09-24 | Iniziato | Jefferies | Buy |
| 2019-09-06 | Iniziato | H.C. Wainwright | Buy |
| 2019-02-04 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Reiterato | Stifel | Hold |
| 2018-05-31 | Downgrade | Stifel | Buy → Hold |
| 2018-03-09 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Iniziato | Stifel | Buy |
| 2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-04-21 | Iniziato | FBR Capital | Outperform |
| 2014-01-13 | Downgrade | Stifel | Buy → Hold |
| 2013-08-09 | Downgrade | Janney | Buy → Neutral |
| 2013-08-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-01-06 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Aggiornamento | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Mostra tutto
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
Corcept Therapeutics (CORT) Sees Significant Drop of 13.3% - GuruFocus
Why Corcept (CORT) Shares Are Falling Today - The Globe and Mail
Corcept Therapeutics (CORT) Shares Drop as Optime Care Ends Dist - GuruFocus
Corcept Therapeutics (CORT) Adjusts Korlym Distribution Strategy - GuruFocus
How sentiment analysis helps forecast Corcept Therapeutics Incorporated2025 Retail Activity & Real-Time Volume Triggers - newser.com
Corcept Therapeutics (CORT) Shares Drop Amid Market Activity - GuruFocus
Analyzing Corcept Therapeutics Incorporated with risk reward ratio chartsQuarterly Market Summary & Community Consensus Trade Alerts - newser.com
Corcept Therapeutics (CORT) Rating Reiterated as 'Buy' by HC Wai - GuruFocus
Volume spikes in Corcept Therapeutics Incorporated stock – what they meanJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
Corcept Therapeutics' (CORT) "Hold (C)" Rating Reiterated at Weiss Ratings - MarketBeat
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight - The Malaysian Reserve
Corcept Therapeutics Incorporated stock trend outlook and recovery pathWeekly Profit Recap & Daily Volume Surge Signals - newser.com
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 4.9%Here's Why - MarketBeat
Pre-ESMO insights: Corcept on platinum-resistant ovarian cancer - pharmaphorum
Corcept Therapeutics Board Member Resigns, Continues as Consultant - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Genmab (GMAB) - The Globe and Mail
Corcept's NDA for its hypercortisolism treatment gets FDA nod - MSN
1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm - The Globe and Mail
Myasthenia Gravis Pipeline Outlook Report 2025: Novel Therapeutics, Clinical Advancements, and Opportunities - The Globe and Mail
'This isn't a dress rehearsal': Why the coming months could be big for a Peninsula drug company that has survived decadesSan Francisco Business Times - The Business Journals
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135 - 富途牛牛
What Fibonacci levels say about Corcept Therapeutics Incorporated reboundWeekly Risk Report & AI Forecasted Entry and Exit Points - newser.com
Will Corcept Therapeutics Incorporated bounce back from current supportQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com
Is a relief rally coming for Corcept Therapeutics Incorporated holdersJuly 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
QRG Capital Management Inc. Acquires 13,829 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Why Corcept Therapeutics Incorporated stock is seen as undervalued2025 Technical Overview & Real-Time Market Sentiment Alerts - newser.com
Visual analytics tools that track Corcept Therapeutics Incorporated performance2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com
Is Corcept Therapeutics Incorporated (HTD) stock undervalued by metricsJuly 2025 Short Interest & Low Risk Growth Stock Ideas - newser.com
Earnings Tell The Story For Corcept Therapeutics Incorporated (NASDAQ:CORT) As Its Stock Soars 27% - 富途牛牛
JSF Financial LLC Makes New Investment in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (CORT): Evaluating Valuation After New Curant Health Partnership and Pipeline Progress - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 5,000 Shares - MarketBeat
Low-Volatility Stocks Underperforming: RSI, ADT, CORT AnalysisNews and Statistics - IndexBox
Here’s What Makes Corcept Therapeutics (CORT) an Attractive Investment? - Yahoo Finance
Synergy Asset Management LLC Raises Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Downgraded by Zacks Research to Strong Sell - MarketBeat
Public Employees Retirement System of Ohio Boosts Stock Holdings in Corcept Therapeutics Incorporated $CORT - Defense World
Will Corcept Therapeutics Incorporated (HTD) stock see insider accumulationJuly 2025 Update & Community Supported Trade Ideas - newser.com
Wealth Enhancement Advisory Services LLC Buys 5,693 Shares of Corcept Therapeutics Incorporated $CORT - Defense World
Why Corcept (CORT) Stock Is Trading Up Today - TradingView
Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym? - Yahoo
How moving averages guide Corcept Therapeutics Incorporated trading2025 Investor Takeaways & Risk Controlled Stock Pick Alerts - newser.com
Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics - Business Wire
Published on: 2025-10-01 03:29:23 - newser.com
Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Corcept Therapeutics Inc Azioni (CORT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Guyer William | Chief Development Officer |
Oct 07 '25 |
Option Exercise |
21.65 |
20,000 |
433,000 |
25,287 |
| Guyer William | Chief Development Officer |
Oct 07 '25 |
Sale |
89.94 |
20,000 |
1,798,782 |
5,287 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):